Open access
Open access
Powered by Google Translator Translator

Safety analysis of RCTs showed Alzheimer’s drug Aducanumab caused brain swelling in 35% of patients, and 26.0% experienced associated symptoms (e.g., headache, confusion, dizziness, and nausea).

24 Nov, 2021 | 08:35h | UTC

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease – JAMA Neurology

Commentary: Biogen Alzheimer’s drug shows brain swelling in 35% of patients – MedicalXpress


Commentary on Twitter


Stay Updated in Your Specialty

No spam, just news.